 Vol.51, No.3, Feb. 2024 |
Data science from the view of the Regulatory Science and Open Science: Theory and human resource development
～Pre-symposium for the establishment of Interfaculty Initiative in Regulatory Science of Biomedical Science and Engineering, Gunma University～ |
| Vol. 51, Suppl 39, 2024 |
| Patient involvement in the development, regulation and safe use of medicines: Report of the CIOMS Working Group XI |
| Vol.51, No.2, Oct. 2023 |
| The First Annual Conference of the Society for Health Data Science |
| Vol.51, No.1, Jul. 2023 |
| Frontier of Clinical Medicine as Predictive Science |
| Vol.50, No.4, Feb. 2023 |
| Data science and research ethics to achieve the SDGs: The future of regulatory science and academic journalss |
| Vol.50, No.3, Dec. 2022 |
| The 1st Bioethics Seminar Development of bioethics and SDGs / The 2nd Bioethics Seminar Patient-oriented Bioethics |
| Vol.50, No.2, Oct. 2022 |
| LHSI - the first anniversary commemoration symposium |
| Vol.50, No.1, Jun. 2022 |
| The current state of the legal framework for research involving humans: International and domestic analysis |
| Vol.49, No.3, Feb. 2022 |
The 12th Annual Meeting of the Japanese Association of Pharmaceutical Medicine 2021 /
Perspectives for overcoming the COVID-19 pandemic: Science, society and medicine: the 2nd session |
| Vol.49, Suppl XXXVIII 2021 |
| COVID-19 and bioethics Part 3: Pandemic and research ethics－Democracy, placebo and post-trial access |
| Vol.49, No.2, Sep. 2021 |
Research Meeting and Webinar on Cutaneous Leishmaniasis (CL):
Research and development for neglected diseases and associated social issues |
| Vol.49, No.1, May 2021 |
The effects on sales volume share of value-added generic drugs
～A complex analysis of pharmaceutical companies’ motivation to develop value-added generic drugs～ |
| Vol.48, Suppl XXXVII 2021 |
| The real status of Japan’s “2040 issue”: The role and mission of TRI / Road to Learning Health Society |
| Vol.48, No.3, Dec. 2020 |
| Perspectives for overcoming the COVID-19 pandemic: Science, society, and medicine |
| Vol.48, No.2, Oct. 2020 |
| Medical Innovation and Longevity (the 2nd session): “Centenarian heart” and “cancer genome medicine” |
| Vol.48, No.1, Jun. 2020 |
Presidential Symposium in the 40th Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics, 2019
International Collaborative Research and New Trends of Research Ethics /
The 120th Pharmaceutical Study Group Meeting Ethics of international collaborative research: Perspectives from Brazil |
| Vol.47, No.3, Feb. 2020 |
The 2nd meeting on the future perspective of the pharmaceutical industry utilizing Real-World Data and Digital Health /
Methodology of risk-benefit assessment and standardization of voting options in IRBs /
The mission and experience of layperson members of the IRB/EC in Korea and Japan |
| Vol.47, No.2, Nov. 2019 |
| The 19th International Conference in Pharmaceutical Medicine (ICPM) 2018 (Tokyo): The Future of Medicines Development |
| Vol.47, Suppl XXXVI 2019 |
Achievements of AMED and exponential research and development in Japan /
The Steps to Disease Control: University’s mission to establish an R&D ecosystem |
| Vol.47, No.1, Jun. 2019 |
Product development and innovation in the era of Digital Health /
Academia-initiated product development and the Clinical Trials Act |
| Vol.46, No.3･4, Feb. 2019 |
Clinical trial data sharing; Clinical Trial Act in Japan / FDA・EMA Guidance on botanical/herbal product development／
From the symposium titled “Product development and research ethics: the past, present and future”
at the 16th annual meeting of the Japanese Society for Science and Technology Studies |
| Vol.46, No.2, Sep. 2018 |
Perspectives toward global health: Life-saving portfolios ／
Front line of academia-initiated product development / Regulatory considerations in Japan and the US |
| Vol.46, No.1, Jun. 2018 |
Actual status and future perspective of clinical trial data sharing－Ethics, credibility, and available technology for trial data linkage－ /
The past, present and future of bioethics and research ethics (Part VI) |
| Vol.45, No.4, Feb. 2018 |
Paradigms shift of drug discovery, development and lifetime management (Part II) /
The past, present and future of bioethics and research ethics (Part V) |
| Vol.45, No.3, Nov. 2017 |
Partnership for NTDs drug discovery originated in Japan /
The past, present and future of bioethics and research ethics (Part IV) |
| Vol.45, No.2, Aug. 2017 |
5th World Centenarian Initiative International Symposium on Stroke /
The past, present and future of bioethics and research ethics (Part III) |
| Vol.45, No.1, Apr. 2017 |
The past, present and future of bioethics and research ethics (Part II) /
2nd Taiwan-Japan Academic Research Organization Workshop / ASIA ARO Network Workshop |
| Vol.44, No.4, Feb. 2017 |
Overcoming neurodegenerative diseases by innovative therapeutic developments /
4th World Centenarian Initiative 2nd Medical Technological Innovation Symposium in Hirosaki /
Toward the global standardization of molecular imaging biomarkers |
| Vol.44, No.3, Dec. 2016 |
Paradigms shift of drug discovery, development and lifetime management /
Taiwan-Japan Academic Research Organization Workshop 2015 /
3rd World Centenarian Initiative International Symposium on Amyotrophic Lateral Sclerosis |
| Vol.44, No.2, Jun. 2016 |
The 14th Setouchi International Conference on Clinical Trials /
The past, present and future of bioethics and research ethics (Part I) |
| Vol.44, No.1, Apr. 2016 |
2nd World Centenarian Initiative International Symposium on Alzheimer's Diseases Prevention Strategy /
The 30th Japan Association for International Health Congress 2015 Trend in global health and infectious diseases |
| Vol.43, No.2, Jan. 2016 |
Rare and Intractable Diseases Translational Research Conference 2014 Toward the New Horizon of Rare Disease /
Consolidated strategic meeting for cancer research and management in disruptive innovation era |
| Vol.43, Suppl XXXV 2015 |
| Public Debriefing Session 2014 |
| Vol.43, No.1, Aug. 2015 |
The 33rd Aso-Kujyu Conference on Clinical Pharmacology /
Consolidated Strategic Meeting on Development of Next-generation Cancer Molecular-targeted Therapy /
The 2nd Translational Research Center Workshop /
The challenge of developing new treatments for NTDs originating from Japan |
| Vol.43, Suppl XXXIV 2015 |
| Moving beyond the Comfort Zone |
| Vol.42, Suppl XXXIII 2014 |
| Public Debriefing Session 2013 |
| Vol.42, No.2, Oct. 2014 |
The 12th Setouchi International Conference on Clinical Trials /
The 32nd Aso-Kujyu Conference on Clinical Pharmacology /
Medical Innovation Management and the trend of data standardization |
| Vol.42, No.1, Jul. 2014 |
Overcoming neuronal system refractory diseases: The current situation and
future prospects for the development
of innovative therapies for spinal cord injury / Translational Research Center Workshop |
| Vol.42, Suppl XXXII 2014 |
| Next Steps and Actions as one of the Leading Countries |
| Vol.41, No.4, Feb. 2014 |
Reformation of clinical research and medical innovation policies in Japan: Challenges and opportunities /
Reflecting on the credibility of investigator-initiated clinical trials /
The regulations and credibility of investigator-initiated clinical trials in the United States and Europe |
| Vol.41, No.3, Jan. 2014 |
The 3rd International Symposium of Early Stage Clinical Trial /
Urgent special topic Opinions on the concept paper of integrating epidemiological and clinical guidelines |
| Vol.41, No.2, Oct. 2013 |
The 11st Setouchi International Conference on Clinical Trials /
Expert Conference on the Revision of the Declaration of Helsinki in Tokyo /
Neurosurgical treatment of psychiatric disorders |
| Vol.41, No.1, Jul. 2013 |
| Public Debriefing Session 2012 |
| Vol.40, No.2, Mar. 2013 |
Dawning of the “Sunshine Act”: Towards a new phase of conflict of interest
management /
The 2nd International Symposium of Early Stage Clinical Trial /
The 31st Aso-Kuju Conference on Clinical Pharmacology |
| Vol.40, No.1, Oct. 2012 |
New trend of clinical trial and clinical research /
The 10th Setouchi International Conference on Clinical Trials |
| Vol.40, Suppl XXXI 2012 |
| Public Debriefing Session 2011 |
| Vol.40, Suppl XXX 2012 |
| Innovative Strategies for Enhancing Regional Drug Development as a Global Drug Development |
| Vol.39, No.3, Mar. 2012 |
| The 30th Aso-Kuju Conference on Clinical Pharmacology / First-in-Human Trial Seminar & Workshop |
| Vol.39, No.2, Oct. 2011 |
| Public Debriefing Session 2010 / International symposium of early stage
clinical trial in Beppu |
| Vol.39, No.1, Jun. 2011 |
| The status and perspectives of compensation for research-related injuries |
| Vol.39, Suppl XXIX 2011 |
| Innovative Strategies for Future Objectives |
| Vol.38, No. 4, Mar. 2011 |
The international conference in Matsuyama for promoting global clinical new drug developments /
Consensus meeting for adipose tissue derived stem cell therapy |
| Vol.38, No. 3, Oct. 2010 |
| The 8th Translational Research Educational Program / Public Debriefing Session 2009 |
| Vol.38, No. 2, Sep. 2010 |
| The use of Bayesian statistics in clinical trials |
| Vol.38, No. 1, Jun. 2010 |
| ICH-S7B, E14: The notifications in Japan and their impact on new drug development |
| Vol.37, Suppl XXVIII 2010 |
| Significance of Asian Studies in Simultaneous Global Clinical Trials |
| Vol.37, No.2, Feb. 2010 |
The international meeting for promotion of global clinical development in Tokyo
What is the true endpoint of global clinical trials and how do we manage? |
| Vol.37, No.1, Oct. 2009 |
10th annual meeting of the Japan Society of Clinical Pharmacological Studies /
The 27th Aso-Kujyu Conference on Clinical Pharmacology |
| Vol.37, Suppl XXVII 2009 |
| Learning from Experience and New Challenges for the Future |
| Vol.36, Suppl XXVI 2009 |
| Clinical science : Principles and practice－Science, law and humanity－ |
| Vol.36, No.3, Apr. 2009 |
| Microdosing clinical trials of biologics |
| Vol.36, No.2, Dec. 2008 |
| Drug development and Medical Research Act in the Netherlands |
| Vol.36, No.1, Aug. 2008 |
The symposium on Deep Brain Stimulation (DBS) therapy for Psychiatric Disorders
At the 47th meeting of the Japan Society for Stereotactic and Functional Neurosurgery |
| Vol.35, No.3, Jun. 2008 |
| J-CLIPNET - Bases for early phase global clinical development |
| Vol.35, No.2, Dec. 2007 |
| The international meeting for promotion of global clinical development in Beppu |
| Vol.35, No.1, Sep. 2007 |
| A handbook for IRB members |
| Vol.35, Suppl XXV 2007 |
| Japan's Critical Path Opportunities |
| Vol.34, No.3, May 2007 |
| Safety information: reporting, dissemination, and analysis |
| Vol.34, No.2, Apr. 2007 |
| What is the future of obstetric medicine? |
| Vol.34, No.1, Feb. 2007 |
| CIOMS Guidelines for Biomedical Research |
| Vol.34, Suppl XXIV 2006 |
| What is the TGN 1412 case ? |
| Vol.33, No.3, Oct. 2006 |
| Basis of translational research: Academia-oriented clinical trials and new drug and medical technology development |
| Vol.33, Suppl XXIII 2006 |
| Development, Evaluation and Approval of New Drugs |
| Vol.33, No.2, Apr. 2006 |
| Position and role of the Asian and Oceanic regions in drug development |
| Vol.33, No.1, Dec. 2005 |
| ARO and IRB: Business-academia collaboration |
| Vol.32, No.2・3, Sep. 2005 |
| Risk management of pharmaceuticals－product management and project management－ |
| Vol.32, Suppl XXII 2005 |
| Global Development Strategies of New Drugs |
| Vol.32, No.1, Apr. 2005 |
| Clinical trial registration and the issue of "Mixed health insurance" |
| Vol.32, Suppl XXI 2004 |
Scientific and ethical evaluation of regenerative medicine
Focus on bone marrow and fetal stem cell clinical research |
| Vol.31, No.3, Sep. 2004 |
| Actual status of the new drug approval review system |
| Vol.31, Suppl XX 2004 |
| Forefront of New Drug Development Strategies |
| Vol.31, No.2, Apr. 2004 |
| The regulatory situations of clinical trials in the US, Europe and Asia |
| Vol.31, No.1, Dec. 2003 |
| The changing situation of clinical trials and support systems: Actual problems and how to solve them |
| Vol.30, No.2･3, Sep. 2003 |
| Clinical research in the "Bio-Genome Century" and the revised Pharmaceutical Affairs Law |
| Vol.30, Suppl XIX 2003 |
| Simultaneous, Worldwide Development Strategies |
| Vol.30 Suppl XVIII 2003 |
| 有害事象の診断学－医薬品と有害事象との因果関係判定の手引－ |
| Vol.30, No.1, Oct. 2002 |
Quality assurance of investigator-oriented clinical research in Japan
－Current status and efforts towards future development－ |
| Vol.29, No.2･3, May 2002 |
| Knowledge management and knowledge sharing |
| Vol. 29, Suppl XVII 2002 |
| Bridging Strategies and Pharmacogenomics |
| Vol. 29, No. 1, Nov. 2001 |
| Drug safety-current status and future perspectives |
| Vol. 29, Suppl XVI 2001 |
| Clinical Evaluation of OTC Drugs and Traditional Drugs |
| Vol. 28, Suppl XV 2001 |
| Bridging Strategies |
| Vol. 28, No. 3, Jun 2001 |
| The 2000 revision to the Declaration of Helsinki and ethics in this era of globalization |
| Vol. 28, No. 2, Jan. 2001 |
| Support systems for clinical trials under the new GCP |
| Vol. 28, No. 1, Oct. 2000 |
| External quality assurance in clinical trials |
| Vol. 27, Suppl XIV 2000 |
| World wide view on development and evaluation of switched and direct OTC |
| Vol. 27, No. 3, Apr. 2000 |
| Information disclosure on clinical trials and international public health |
| Vol. 27, No. 2, Dec. 1999 |
| Present Status of Clinical Trials and Supporting Systems in Three Regions (Japan, the US and Europe) |
| Vol. 27, No. 1, Sep. 1999 |
| Application of Statistical Principles for Clinical Trials |
| Vol. 26, Suppl XIII 1999 |
| Evidence of Off-Label Use of Drug |
| Vol.26, No.3, Feb. 1999 |
| |
| Vol.26, No.2, Nov. 1998 |
| |
| Vol.26, No.1, Jul. 1998 |
| |
| Vol.25, No.2･3, Apr. 1998 |
| |
| Vol.25, No.1, Sep. 1997 |
| |